about
The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosisA model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients.Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclEndothelial injury in vasculitides.GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides.Proteomic identification of VEGF-dependent protein enrichment to membrane caveolar-raft microdomains in endothelial progenitor cells.Brn-3a, a neuronal transcription factor of the POU gene family: indications for its involvement in cancer and angiogenesis.Surface plasmon resonance as detection tool for lipids lateral mobility in biomimetic membranes.The plasminogen activation system in inflammation.The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation.Endothelial sphingosine kinase/SPNS2 axis is critical for vessel-like formation by human mesoangioblasts.Inhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells.Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in miceEndothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth.FGF2-mediated upregulation of urokinase-type plasminogen activator expression requires a MAP-kinase dependent activation of poly(ADP-ribose) polymerase.Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.Interaction of urokinase-type plasminogen activator with its receptor rapidly induces activation of glucose transporters.Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells.Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells.Inhibition of spontaneous growth and induced differentiation of murine erythroleukaemia cells by paraquat and atrazine.Urokinase and its receptor in follicular and inflammatory cysts of the jaws.Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts.TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesisErratum: Publisher Correction to: delivery systems of CRISPR/Cas9-based cancer gene therapyA new electrophoretic method for the complete separation of all known animal glycosaminoglycans in a monodimensional runLaminin and fibronectin distribution in normal and pathological human muscleAdhesion-dependent heparin production by plateletsInvolvement of chondroitin sulphate in preventing adhesive cellular interactionsCell surface glycosaminoglycans in normal and leukemic leukocytesIn vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cellsInvolvement of glycosaminoglycans in detachment of early myeloid precursors from bone-marrow stromal cellsGlycosaminoglycan changes involved in polymorphonuclear leukocyte activation in vitroProduction of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptorSynoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surfaceNon-enzymatic activities of proteases: from scepticism to realityGrowth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic systemuPAR in angiogenesis regulation
P50
Q28279380-A7DCFD9A-FED6-4203-BCE5-721415653EC6Q30478833-AF8AFE69-6835-49CF-81F3-EE49BA072FCBQ33264935-8F65F164-7925-4C72-9E61-99A2682335C4Q33790094-67C2152B-D3B8-4005-9682-7F1B051D37EBQ34505275-9870921C-1995-44DB-9B93-D6972BFA23ADQ34661515-D6A825D3-6EF2-4C93-876B-C5201B269713Q34982937-C2CE7C7C-43B1-483D-A478-433B963D1FE1Q36464030-27C35066-312C-4799-9AF8-2004F10B44B6Q37175368-9163DB40-BA2F-4063-B0F8-6A9828470435Q37895300-883229E5-203A-44ED-B773-A7572DE633B9Q38878001-B291BB17-6521-4642-86BC-5CFE2FA8D93AQ38908272-3637454A-651F-402F-B719-A4836861A229Q39706283-3F2FBBE3-7E5C-4CFB-8426-6EE999138236Q39793015-33F6E49A-36C3-4257-AED4-9B971F931C2EQ40026208-1BD269B6-DE6E-482E-9E40-1A42F581E255Q40416273-C7A2E5FE-B9A3-4949-802D-0AE0EC52A51EQ40511726-68191F52-4D50-4E5F-8367-D2634EDC5557Q40571595-BD40A9A4-A75F-48B3-9752-6903838BE058Q41120487-E278FDA0-CC9B-4870-A34B-AC980C0551FCQ41577789-DBDC6B1A-95BF-4B29-8BFB-D0F985D7DBFCQ45304157-4D1DF049-A5F8-4D75-BCB4-C79C3CE231F1Q45555792-FE147A3F-495C-4C98-B251-8AFF616D0B58Q50890274-815F2F6A-2A80-4BF2-8660-D019E98A17B6Q53311342-172B5230-6724-4D59-97BD-6027BD42F5E7Q54374381-F5A5A158-8A96-4E75-B715-50F48547836DQ56893657-466F5FBC-4A21-45E3-B67F-59FB2E681605Q64071032-a2521196-4093-b0c5-e889-42c42c283dccQ66978488-A100A444-F71B-495B-80DD-F9093BD8E067Q70292643-B6751C9E-F694-484B-9E7D-6356C471F815Q70294545-D2356C19-5336-48C2-8DA6-1A9CF66C9699Q70440165-E4D381D6-57C8-4AEF-99B2-3944246E104BQ71208596-05494722-BD26-4650-86D6-49B7FFA75AB4Q71227566-C8E676BD-4ED1-4AD5-8CC2-E4922455FCD4Q71561794-75B6FD48-90BC-4C6A-864D-EE8F3B577DE6Q71606414-F805032E-C342-4746-84F0-8AF133847A2CQ72106859-BC5EC569-9D79-4375-AB05-59E33DDA0B03Q77152152-B7898512-BA75-4DA8-88E2-36CC971EB69BQ77865541-6EFD3241-BAA9-4722-8F9C-59A052CADB0AQ77865572-98DA7159-9B9C-4CC1-AF34-FDDAA25D1719Q83865748-F6EDE83B-F92F-4221-B9D1-D36869D0F99D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Del Rosso
@ast
Mario Del Rosso
@en
Mario Del Rosso
@es
Mario Del Rosso
@nl
Mario Del Rosso
@sl
type
label
Mario Del Rosso
@ast
Mario Del Rosso
@en
Mario Del Rosso
@es
Mario Del Rosso
@nl
Mario Del Rosso
@sl
prefLabel
Mario Del Rosso
@ast
Mario Del Rosso
@en
Mario Del Rosso
@es
Mario Del Rosso
@nl
Mario Del Rosso
@sl
P106
P1153
7003854500
P21
P31
P496
0000-0002-2980-2731